asthma

AstraZeneca, Amgen's asthma launch Tezspire picks up backing from England's NICE
AstraZeneca, Amgen's asthma launch Tezspire picks up backing from England's NICE
Fierce Pharma
AstraZeneca
Amgen
Tezspire
UK
NICE
asthma
severe asthma
Flag link:
Dupixent kicks off 2023 as top pharma brand for ad impressions
Dupixent kicks off 2023 as top pharma brand for ad impressions
Medical Devices and Diagnostics Industry
Sanofi
Dupixent
asthma
pharma advertising
Flag link:
AstraZeneca and Avillion win approval for new asthma rescue treatment in adults
AstraZeneca and Avillion win approval for new asthma rescue treatment in adults
Endpoints
AstraZeneca
Avillion
Airsupra
asthma
FDA
Flag link:
Could AstraZeneca's Asthma Drug Candidate Generate Billions?
Could AstraZeneca's Asthma Drug Candidate Generate Billions?
Motley Fool
AstraZeneca
asthma
PT027
Flag link:
Yes, no, maybe: FDA panel delivers mixed verdict on AstraZeneca's asthma rescue medication
Yes, no, maybe: FDA panel delivers mixed verdict on AstraZeneca's asthma rescue medication
Fierce Biotech
AstraZeneca
asthma
PT027
FDA
Flag link:
Sanofi, Regeneron team with Broadway actor for digital severe asthma program
Sanofi, Regeneron team with Broadway actor for digital severe asthma program
Medical Marketing and Media
asthma
severe asthma
Sanofi
Regeneron
pharma marketing
Flag link:
AstraZeneca debuts annoying purple ‘Phil’ creatures, personified asthma eosinophils ‘behaving badly’
AstraZeneca debuts annoying purple ‘Phil’ creatures, personified asthma eosinophils ‘behaving badly’
Endpoints
pharma marketing
DTC advertising
AstraZeneca
eosinophilic asthma
asthma
Fasenra
Flag link:
Sanofi’s asthma therapy shows consistent safety profile in Phase III trial
Sanofi’s asthma therapy shows consistent safety profile in Phase III trial
Clinical Trials Arena
Sanofi
Dupixent
pediatric
clinical trials
severe asthma
asthma
Flag link:
Moving Away from Asthma and COPD, Novartis Hones in on 20 Approvals by 2026
Moving Away from Asthma and COPD, Novartis Hones in on 20 Approvals by 2026
BioSpace
Novartis
asthma
COPD
Flag link:
Transpire Bio signs with Recipharm for inhaled medicine development
Transpire Bio signs with Recipharm for inhaled medicine development
European Pharmaceutical Review
Transpire Bio
Recipharm
asthma
COPD
inhaled drugs
drug development
Flag link:
Novartis looking for new homes for midphase asthma, eye disease and NASH assets after pipeline review
Novartis looking for new homes for midphase asthma, eye disease and NASH assets after pipeline review
Fierce Biotech
Novartis
asthma
NASH
Retinitis pigmentosa
Flag link:
Areteia gets $350M to turn failed ALS drug into a therapy for severe asthma
Areteia gets $350M to turn failed ALS drug into a therapy for severe asthma
MedCity News
Areteia Therapeutics
ALS
asthma
eosinophilic asthma
Flag link:
Upstream Bio Launches with $200M Series A Financing to Advance Novel Therapeutics for Allergic and Inflammatory Diseases
Upstream Bio Launches with $200M Series A Financing to Advance Novel Therapeutics for Allergic and Inflammatory Diseases
BioSpace
Upstream Bio
funding
asthma
allergies
Flag link:
Masimo's (MASI) PVi Favored by New Study for Pediatric Patients
Masimo's (MASI) PVi Favored by New Study for Pediatric Patients
Yahoo/Zacks.com
Masimo
Medtech
devices
PVi
pediatric
asthma
Flag link:
GSK 'schemed' FDA's drug-device approval pathway to deflect asthma inhaler generics, lawsuit claims
GSK 'schemed' FDA's drug-device approval pathway to deflect asthma inhaler generics, lawsuit claims
Fierce Pharma
GSK
FDA
drug-device combos
Missouri
legal
asthma
inhalers
Flag link:
AstraZeneca, Avillion ‘first-in-class’ combination inhaler shines in Phase 3 trial
AstraZeneca, Avillion ‘first-in-class’ combination inhaler shines in Phase 3 trial
Pharmaforum
AstraZeneca
Avillion
clinical trials
calbuterol/budesonide
inhalers
asthma
Flag link:
Teva suffers setback on in-house asthma program as a PhII study is halted early due to futility
Teva suffers setback on in-house asthma program as a PhII study is halted early due to futility
Endpoints
Teva Pharmaceutical
clinical trials
asthma
TEV-48574
Flag link:
AstraZeneca, Amgen tap Brand Institute in new naming twist for their freshly approved Tezspire
AstraZeneca, Amgen tap Brand Institute in new naming twist for their freshly approved Tezspire
Fierce Pharma
Amgen
AstraZeneca
Broad Institute
asthma
Tezspire
drug names
Flag link:
4D Pharma sees positive data from early stage asthma trial
4D Pharma sees positive data from early stage asthma trial
Biopharma Reporter
4D Pharma
clinical trials
asthma
LBPs
Flag link:
Viatris gets shot to shed infringement claims in long-running patent kerfuffle on AstraZeneca's Symbicort
Viatris gets shot to shed infringement claims in long-running patent kerfuffle on AstraZeneca's Symbicort
Fierce Pharma
Viatris
generics
Symbicort
AstraZeneca
patents
COPD
asthma
Flag link:

Pages